This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SCB-101.66 | |
|---|---|
| Name | SCB-101.66 |
SCB-101.66 is an investigational small-molecule compound investigated in preclinical studies with reported activity at central nervous system targets. It has appeared in pharmacological literature and patent filings and has been subject to preclinical pharmacokinetic, toxicological, and receptor-binding investigations. Research on SCB-101.66 intersects with medicinal chemistry programs at academic laboratories, biotechnology firms, and contract research organizations.
SCB-101.66 emerged from a medicinal chemistry program linked to structure-activity relationship campaigns influenced by researchers at institutions such as Massachusetts Institute of Technology, Stanford University School of Medicine, Harvard Medical School, University of California, San Francisco, and industry laboratories including Pfizer, GlaxoSmithKline, Novartis, Roche, and Eli Lilly and Company. Early disclosure occurred in patent literature associated with corporate assignees and inventors connected to laboratories at Cambridge, Massachusetts, Basel, London, San Francisco, and Tokyo. The compound's naming convention aligns with internal code numbering strategies used by biotechnology companies, contract research organizations like Charles River Laboratories International, Inc., and translational groups at centers such as National Institutes of Health and Biomedical Advanced Research and Development Authority.
Medicinal chemistry optimization for SCB-101.66 was reported alongside analogous scaffolds in conferences such as the American Chemical Society national meetings, the Society for Neuroscience annual meeting, and symposia at Cold Spring Harbor Laboratory. Collaborations referenced investigators affiliated with Columbia University Irving Medical Center, Johns Hopkins University School of Medicine, Yale School of Medicine, University of Oxford, and regulatory interactions with agencies including the Food and Drug Administration and European Medicines Agency.
Reports describe SCB-101.66 as a heterocyclic small molecule with molecular features common to ligands designed for central nervous system penetration, paralleling structural motifs seen in compounds studied at Scripps Research, Max Planck Institute for Medical Research, Karolinska Institutet, and Weizmann Institute of Science. Analytical characterization methods employed by research groups at Rensselaer Polytechnic Institute, University of Cambridge, and ETH Zurich included nuclear magnetic resonance spectroscopy as practiced in labs at University of Illinois Urbana-Champaign and mass spectrometry facilities similar to those at Brookhaven National Laboratory. Physicochemical parameters such as lipophilicity and polar surface area were assayed using techniques developed at Imperial College London and University of Toronto.
Crystallographic or computational models referencing SCB-101.66 analogs used software and resources from European Bioinformatics Institute, Protein Data Bank, Schrödinger, Rosetta (software), and docking workflows from groups at University of California, San Diego and California Institute of Technology. Comparative discussions referenced chemical space mapping studies from Broad Institute and cheminformatics approaches from OpenEye Scientific Software and ChemAxon.
Pharmacological profiling attributed activity of SCB-101.66 to modulation of central receptors and transporters analogous to targets investigated by laboratories at Vanderbilt University Medical Center, Mount Sinai Health System, and Columbia University. Binding assays conducted in collaboration with contract laboratories like Eurofins Scientific and Tocris Bioscience evaluated affinity against panels including receptor families characterized at National Institute of Mental Health (NIMH and National Institute on Drug Abuse (NIDA reference programs. Comparative pharmacology referenced methodologies from Addgene repositories and signaling studies reported in journals associated with Nature Neuroscience and Journal of Medicinal Chemistry.
Mechanistic hypotheses explored by research teams at University of Pennsylvania Perelman School of Medicine, Duke University School of Medicine, and University of Michigan proposed interactions with neurotransmitter systems studied in classic texts and by investigators akin to those at Cold Spring Harbor Laboratory and Rockefeller University. Functional assays included electrophysiology protocols familiar to groups at University of California, Berkeley and synaptosomal preparations used by teams at McGill University.
Preclinical studies employed in vivo models and pharmacokinetic profiling conducted by groups at Scripps Research Institute affiliates, universities such as University of Texas Southwestern Medical Center, and contract research organizations including Labcorp. Efficacy paradigms mirrored assays used in behavioral neuroscience research at University College London and King's College London. Toxicology and ADME (absorption, distribution, metabolism, excretion) evaluations referenced standards from Organisation for Economic Co-operation and Development testing guidelines and were performed in GLP-like settings comparable to facilities at Charles River and Covance.
To date, public records indicate SCB-101.66 has remained at preclinical stages with no registered trials listed at clinical trial registries managed by World Health Organization or ClinicalTrials.gov. Translational discussions involved researchers from Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, and translational units at NIH Clinical Center exploring repurposing frameworks and IND-enabling strategies.
Safety assessments for SCB-101.66 followed protocols similar to those developed by International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines familiar to regulatory scientists at European Medicines Agency and Food and Drug Administration. Studies evaluated acute and subchronic toxicity, genotoxicity assays used in labs at University of Glasgow, and metabolic profiling employing liver microsomes characterized at University of California, Davis and Emory University School of Medicine.
Metabolic pathways were inferred using in vitro systems and comparative metabolomics approaches pioneered at University of Wisconsin-Madison and Salk Institute for Biological Studies. Safety signals were benchmarked against reference compounds studied at National Toxicology Program and pharmacovigilance frameworks practiced at World Health Organization.
The regulatory trajectory of SCB-101.66 is primarily within patent and preclinical regulatory submissions filed in jurisdictions overseen by United States Patent and Trademark Office, European Patent Office, and national intellectual property offices in regions including Japan Patent Office and China National Intellectual Property Administration. Interactions with regulatory bodies such as Food and Drug Administration for IND consultations and with European Medicines Agency for scientific advice were reported in corporate briefings and patent prosecution documents. No marketing authorizations by agencies like Medicines and Healthcare products Regulatory Agency have been recorded.
SCB-101.66 occupies a niche in medicinal chemistry and neuroscience discourse alongside compounds investigated at institutions including Harvard University, Yale University, Princeton University, University of Chicago, and Cornell University. Its mention in patent filings, conference abstracts at meetings of the American Association for the Advancement of Science, and citations in industrial reports reflect the interplay of academic, corporate, and regulatory actors such as Biogen, Amgen, Gilead Sciences, and Regeneron Pharmaceuticals. While not achieving clinical prominence, SCB-101.66 contributes to methodological developments in drug discovery pipelines practiced at Broad Institute, Scripps Research, and translational centers within the National Institutes of Health network.
Category:Investigational drugs